<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736837</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-L004</org_study_id>
    <nct_id>NCT03736837</nct_id>
  </id_info>
  <brief_title>Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC</brief_title>
  <acronym>ALTER-L004</acronym>
  <official_title>A Multi-center, One-arm Clinical Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive Advanced NSCLC. The Trial Aims to Evaluate the Efficacy and Safety of This Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in
      patients with sensitive EGFR mutations advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib Hydrochloride is a kind of innovative medicines approved by State Food and Drug
      Administration（CFDA:2011L00661） which was developed by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS（Progress free survival）</measure>
    <time_frame>each 42 days up to PD or death (up to 24 months)</time_frame>
    <description>The PFS time is defined as time from enrollment to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of : &quot;death&quot;, &quot;last tumor assessment&quot;, &quot;last follow up date&quot; or &quot;last date in drug log&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS（Overall Survival）</measure>
    <time_frame>From enrollment until death (up to 24 months)</time_frame>
    <description>OS was defined as time from date of enrollment to date of death due to any cause. For participants still alive at the time of analysis, OS time was censored on last date that participants were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（Objective Response Rate）</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule Plus Icotinib Hydrochloric Tablet by enhanced CT/MRI scan every two cycles. Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR（Disease Control Rate）</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule Plus Icotinib Hydrochloric Tablet by enhanced CT/MRI scan every two cycles. Disease Control Rate (DCR) defined as the percentage of participants with Disease Control best overall response (complete response, partial response or stable disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Until 30 day safety follow-up visit</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib Plus Icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Plus Icotinib</intervention_name>
    <description>Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).
Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.</description>
    <arm_group_label>Anlotinib Plus Icotinib</arm_group_label>
    <other_name>A+T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent

          2. 18-75years，ECOG PS：0-2，Life expectancy of more than 3 months，with measurable lesion (
             RECIST1.1)

          3. Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB,
             IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC（according to the 8th
             Edition of the AJCC Staging system）with EGFR 19 del and/or 21 L858R gene mutation

          4. Has not received chemotherapy or other targeted therapies；For recurrent disease,
             adjuvant chemotherapy, neoadjuvant chemotherapy or neoadjuvant chemotherapy plus
             adjuvant chemotherapy may be accepted, but recurrence occurs after ≥6 months from
             stopping treatment.

          5. ≥1 target lesion that has not received radiotherapy in the past 3 months and can be
             accurately measured in at least 1 direction；Previously received radiation therapy, but
             the radiotherapy area must be &lt;25% of the bone marrow area, and radiation therapy must
             have closed for at least≥4 weeks at the time of enrollment;

          6. Main organs function is normal

          7. Patients of brain metastases with asymptomatic or mild symptoms can be enrolled

          8. The woman patients of childbearing age must agree to take contraceptive methods during
             the research and within another 8 weeks after treatment. Pregnancy test (blood serum
             test or urine) should be done within 7 days before the research and the result should
             be negative.The man patients who must agree to take contraceptive methods during the
             research and within another 8 weeks after treatment.

        Exclusion Criteria:

          1. Squamous cell carcinoma (including adenosquamous carcinoma); Small Cell Lung Cancer
             (including small cell cancer and other kinds of cancer mixed with non-small cell
             cancer)

          2. ALK-positive NSCLC

          3. Central Lung tumors that Imaging (CT or MRI) shows tumor lesions invade local large
             blood vessels; or with significant pulmonary cavum or necrotizing

          4. Patients with obvious brain metastases, cancerous meningitis, spinal cord compression,
             or with brain or pia mater disease. (patient with brain metastases who have completed
             treatment 14 days before and the symptoms are stable can be Enrolled, also should have
             no cerebral hemorrhage symptoms confirmed by brain MRI, CT or venography evaluation

          5. The patient is participating in other clinical studies or Participated in other
             anti-tumor drug clinical trials within 4 weeks before enrollment

          6. With other active malignancies that require simultaneous treatment

          7. Has a history of malignant tumors. Except for patients with cutaneous basal cell
             carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or orthotopic
             cervical cancer who have undergone curative treatment and have no disease recurrence
             within 5 years after the start of treatment

          8. Patients with adverse reactions derived from previous therapies (excluding hair loss),
             which is over level 1 in CTC AE (4.0)

          9. abnormal blood coagulation (INR&gt;1.5 or PT &gt; ULN + 4s or APTT &gt; 1.5 ULN), with bleeding
             tendency or receiving thrombolytic or anticoagulant therapy

         10. renal insufficiency: urinary protein ≥ ++, or 24-hour urine protein ≥ 1.0g;

         11. The effect of surgery or trauma has been eliminated for less than 14 days before
             enrollment

         12. Severe acute or chronic infections requiring systemic treatment

         13. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial
             infarction above grade II, poorly controlled arrhythmias

         14. Patients with peripheral neuropathy which is over level 2 in CTC AE (4.0), except for
             trauma

         15. respiratory syndrome (dyspnea≥CTC AE 2), severe pleural effusion, ascites, pericardial
             effusion

         16. Long-term unhealed wounds or fractures

         17. Decompensated diabetes or other ailments treated with high doses of glucocorticoids

         18. with kinds of factors which affect oral medicine (e.g. failing to swallow,
             gastrointestinal tract getting resected, chronic diarrhea and ileus)

         19. hemoptysis (daily hemoptysis＞50ml) within 3 months prior to enrollment; or significant
             clinically significant bleeding symptoms or defined bleeding tendency

         20. Thrombosis events occurring within 12 months prior to enrollment

         21. Planned to get systemic anti-tumor therapy during this study；EF-RT was performed
             within 4 weeks before enrollment or limited field radiotherapy within 2 weeks before
             grouping

         22. Hypertension (systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg)
             that is still uncontrollable using two or more combination therapies

         23. History of psychotropic substance abuse and inability to quit or have mental disorders

         24. HIV test positive history or AIDS; untreated active hepatitis; combined with hepatitis
             B and hepatitis C co-infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dingzhi Huang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Provincial People's Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neimenggu Autonomous Region People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neimenggu Medical University Affiliated Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://doi.org/10.1007/s40264-017-0596-0</url>
    <description>Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results</description>
  </link>
  <link>
    <url>http://doi.org/10.1093/annonc/mdw383.86</url>
    <description>NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations</description>
  </link>
  <link>
    <url>https://doi.org/10.1093/annonc/mdy292.063</url>
    <description>Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026</description>
  </link>
  <results_reference>
    <citation>Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.</citation>
    <PMID>25175099</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sensitive EGFR mutations</keyword>
  <keyword>anlotinib</keyword>
  <keyword>icotinib</keyword>
  <keyword>first line</keyword>
  <keyword>cancer</keyword>
  <keyword>non-squamous NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individul participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external indepentent Review Panel. Requesdtors will be required to sign a Data Access Agreement.</ipd_access_criteria>
    <ipd_url>http://www.cttq.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

